NO180636C - Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1 - Google Patents

Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1

Info

Publication number
NO180636C
NO180636C NO910669A NO910669A NO180636C NO 180636 C NO180636 C NO 180636C NO 910669 A NO910669 A NO 910669A NO 910669 A NO910669 A NO 910669A NO 180636 C NO180636 C NO 180636C
Authority
NO
Norway
Prior art keywords
igf
glycosylated
pure
preparation
glycosylated igf
Prior art date
Application number
NO910669A
Other languages
English (en)
Norwegian (no)
Other versions
NO910669D0 (no
NO180636B (no
NO910669L (no
Inventor
Anna Skottner-Lundin
Linda Fryklund
Paer Gellerfors
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO910669D0 publication Critical patent/NO910669D0/no
Publication of NO910669L publication Critical patent/NO910669L/no
Publication of NO180636B publication Critical patent/NO180636B/no
Publication of NO180636C publication Critical patent/NO180636C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO910669A 1988-08-20 1991-02-19 Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1 NO180636C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888819826A GB8819826D0 (en) 1988-08-20 1988-08-20 Glycosylated igf-1
PCT/EP1989/000972 WO1990002198A1 (en) 1988-08-20 1989-08-17 O-glycosylated igf-1

Publications (4)

Publication Number Publication Date
NO910669D0 NO910669D0 (no) 1991-02-19
NO910669L NO910669L (no) 1991-02-19
NO180636B NO180636B (no) 1997-02-10
NO180636C true NO180636C (no) 1997-05-21

Family

ID=10642464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO910669A NO180636C (no) 1988-08-20 1991-02-19 Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1

Country Status (15)

Country Link
US (1) US5273966A (de)
EP (2) EP0429502A1 (de)
JP (1) JP2543998B2 (de)
AT (1) ATE109206T1 (de)
AU (1) AU623675B2 (de)
CA (1) CA1335802C (de)
DE (1) DE68917061T2 (de)
DK (1) DK175360B1 (de)
ES (1) ES2060778T3 (de)
FI (1) FI102282B (de)
GB (1) GB8819826D0 (de)
IE (1) IE65096B1 (de)
NO (1) NO180636C (de)
NZ (1) NZ230383A (de)
WO (1) WO1990002198A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5231178A (en) * 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
JPH06506117A (ja) * 1991-04-01 1994-07-14 メルク　エンド　カンパニー　インコーポレーテッド ピキア（Ｐｉｃｈｉａ）蛋白質分解活性に影響する遺伝子およびその使用
SG46612A1 (en) * 1992-12-02 1998-02-20 Hoechst Ag Process for obtaining proinsulin in processing correctly linked cystine bridges
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8343918B2 (en) * 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
US20120213728A1 (en) * 2009-10-30 2012-08-23 Merck Granulocyte-colony stimulating factor produced in glycoengineered pichia pastoris
US20100172865A1 (en) * 2010-03-18 2010-07-08 Shantha Totada R Methods of enhancing hair growth
ES2674567T3 (es) 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
BR112016005716A2 (pt) 2013-10-02 2017-09-12 Nat Institutes Of Health miméticos de fator de crescimento semelhante à insulina para uso em terapia
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486216T2 (de) * 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.

Also Published As

Publication number Publication date
DK29491A (da) 1991-04-19
NO910669D0 (no) 1991-02-19
DE68917061T2 (de) 1994-11-17
DK29491D0 (da) 1991-02-20
EP0360411B1 (de) 1994-07-27
NO180636B (no) 1997-02-10
EP0360411A1 (de) 1990-03-28
FI910795A0 (fi) 1991-02-19
FI102282B1 (fi) 1998-11-13
CA1335802C (en) 1995-06-06
WO1990002198A1 (en) 1990-03-08
ATE109206T1 (de) 1994-08-15
JP2543998B2 (ja) 1996-10-16
AU4051889A (en) 1990-03-23
EP0429502A1 (de) 1991-06-05
FI102282B (fi) 1998-11-13
NO910669L (no) 1991-02-19
ES2060778T3 (es) 1994-12-01
NZ230383A (en) 1992-01-29
JPH05505514A (ja) 1993-08-19
DE68917061D1 (de) 1994-09-01
IE65096B1 (en) 1995-10-04
AU623675B2 (en) 1992-05-21
IE892652L (en) 1990-02-20
US5273966A (en) 1993-12-28
GB8819826D0 (en) 1988-09-21
DK175360B1 (da) 2004-09-13

Similar Documents

Publication Publication Date Title
EP0336760A3 (de) Knochenwachstum induzierendes Protein
NO973848D0 (no) Fremgangsmåte til fremstilling av hemoglobinliknende protein
AU6701890A (en) Process for the production of biologically active protein
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
DE68916385D1 (de) Stabilisierte Formulierungen mit hydrohoben Proteinen.
AU580973B2 (en) Novel polypeptides with an ``-amylase-inhibiting action, a process for their preparation, their use and pharmaceutical products
AU6733487A (en) Mammalian interleukin-4
CA2066618A1 (en) Plasmids containing dna encoding the amino acid sequence of tcf-ii, transformed cells with the plasmids, and production method of biologically active substance using the transformed cells
FI102282B1 (fi) Menetelmä O-glykosyloidun IGF-1:n valmistamiseksi
KR900700492A (ko) N-헤테로사이클릭 프로필리덴-1,1-비스포스폰산, 이의 제조방법 및 약제학적 조성물
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
DE3686099D1 (de) Analoga von cyclischen hexapeptiden von somatostatin, deren verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
IS3728A7 (is) Hliðstæð aðferð til framleiðslu á 3,3'-dithiobis (própíónsýrum) og esterum þeirra
AU584337B2 (en) Novel lactones, process for their preparation and the use thereof in pest control
DE3685044D1 (de) Analoge interferon-polypeptide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
EP0390849A4 (en) Methyl cellulose pharmaceutical composition
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
EP0351876A3 (de) Zusammensetzung zur Steigerung der Impfungswirkung
DE2965364D1 (en) Alpha-difluoromethyl amino acids and pharmaceutical composition containing the same
NO164973C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive gem-dihalo- og tetrahalo-1,2-diamino-4,9,-diaza-dodecaner.
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
EP0351017A3 (en) Pharmaceutical composition useful for the treatment of cardiovascular diseases
HUT46693A (en) Process for producing dioxabicyclo/3,3,0/oktanon-oxim-ethers and pharmaceutical compositions containing them as active components
ATE75488T1 (de) Analoge interferon-polypeptide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.